SCHEMBL30420018

SCHEMBL30420018

C#CCNc1nc(=O)n(-c2nccnc2C)c2cc(Cl)cc(OC)c12

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 6/20 0.40
▸ GRM1 Q13255 2/20 0.32
▸ MAOB P27338 1/20 0.32
▸ PI4KB Q9UBF8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26485222 1.00 MAT2A (0.40) MAT2AGRM1MAOBPI4KB
SCHEMBL30420252 0.86 MAT2A (0.42) MAT2AGRM1MAOB
SCHEMBL26485221 0.86 MAT2A (0.42) MAT2AGRM1MAOB
SCHEMBL26091386 0.86 MAT2A (0.35) MAT2AGRM1
SCHEMBL30420280 0.86 MAT2A (0.35) MAT2AGRM1
SCHEMBL26485128 0.84 MAT2A (0.50) MAT2AGRM1MAOB
SCHEMBL30418873 0.84 MAT2A (0.50) MAT2AGRM1MAOB
SCHEMBL26485224 0.83 MAT2A (0.36) MAT2A
SCHEMBL30420259 0.83 MAT2A (0.36) MAT2A
SCHEMBL26487645 0.79 MAT2A (0.35) MAT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042890-A1 METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2025-02-06 — — US disclosed
EP-4419506-A1 METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF Insilico Medicine IP Limited (HK) 2024-08-28 — — EP disclosed
CN-118434722-A Methionine adenosyltransferase 2A (MAT 2A) inhibitors and uses thereof 英矽智能科技知识产权有限公司 2024-08-02 — — CN disclosed
WO-2023066283-A1 METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042890-A1 METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF MAT2A, MAT2B, MAT1A MAT2A 1/4885GRM1 323/4885MAOB 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback